Home/Filings/4/0001214659-25-016275
4//SEC Filing

Davis Matthew W. 4

Accession 0001214659-25-016275

CIK 0001398733other

Filed

Nov 11, 7:00 PM ET

Accepted

Nov 12, 9:35 AM ET

Size

7.3 KB

Accession

0001214659-25-016275

Insider Transaction Report

Form 4
Period: 2025-11-10
Davis Matthew W.
Chief Development Officer
Transactions
  • Award

    Common Stock

    2025-11-10+50,00050,000 total
  • Award

    Non-Qualified Stock Option (right to buy)

    2025-11-10+50,00050,000 total
    Exercise: $5.58Exp: 2035-11-10Common Stock (50,000 underlying)
Footnotes (2)
  • [F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
  • [F2]The option will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Issuer

Aquestive Therapeutics, Inc.

CIK 0001398733

Entity typeother

Related Parties

1
  • filerCIK 0002094283

Filing Metadata

Form type
4
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 9:35 AM ET
Size
7.3 KB